Nephros, Inc.

Nephros is a commercial-stage company that develops and markets high-performance water filtration solutions for points of use, primarily focusing on medical-grade water filtration. Its medical filtration portfolio includes two product lines: infection control and dialysis water. The infection control segment offers microfilters (0.1 micron), which retain bacteria, and ultrafilters (0.005 micron), which retain bacteria, viruses, and endotoxins, addressing waterborne pathogens such as Legionella and Pseudomonas. The dialysis segment exclusively uses ultrafilters, providing microbial and endotoxin retention for water and bicarbonate concentrate used in dialysis treatment, where endotoxin control is critical. All medical-grade filters are FDA 510(k)-cleared as Class II medical devices. These filters are used in healthcare settings and other industries including manufacturing, laboratories, aviation, and federal facilities. Additionally, Nephros offers commercial water filters that improve taste and odor, reduce biofilm formation and scale buildup, and remove cysts, particulates, and lead. A new solution has been released, validated for the reduction of Total PFAS (a mixture of seven PFAS compounds including PFOA, PFOS, PFHxS, PFNA, PFHpA, PFBS, and PFDA), enhancing the portfolio's ability to address emerging and persistent waterborne contaminants. Commercial filtration products are applicable across industries and can be used with medical-grade filters for comprehensive water-quality protection. For medical applications, Nephros manufactures ultra- and microfilters using polysulfone hollow fiber membranes that retain microbiological contaminants through physical size exclusion.